Spotlight session: Allogeneic therapies as a pathway to long term scalability

Autologous therapies remain resource-intensive and patient-specific, creating barriers to widespread clinical adoption. Allogeneic platforms offer a potential path to long-term scalability by enabling standardized manufacturing and broader patient reach. This spotlight session examines the scientific, clinical, and regulatory considerations critical to advancing allogeneic therapies. 

Key takeaways: 

• Compare autologous and allogeneic models with respect to scalability and patient access. 

• Explore manufacturing innovations that enable reproducibility and quality control. 

• Assess translational fidelity and predictive validity for allogeneic approaches. 

• Discuss safety margins and immunogenicity considerations in allogeneic therapies. 

• Consider regulatory perspectives on advancing off-the-shelf therapies to the clinic.